Methasan (Methadone Hydrochloride)

Methadone hydrochloride works by fully activating the μ‑opioid receptors in the central nervous system, mimicking the effects of natural endorphins. This activation suppresses opioid cravings and withdrawal, while also providing analgesic effects. Additionally, methadone blocks NMDA receptors, which may help limit tolerance development.

The appropriate dose of Methasan is individualized and set by a qualified prescriber based on the patient’s clinical condition, prior opioid exposure, and response to therapy. Dosage adjustments are made during treatment to achieve optimal control of withdrawal symptoms or pain while minimizing adverse effects.

Methasan is classified as Pregnancy Category C, indicating that risk to the fetus cannot be ruled out and it should be used only if the potential benefit justifies the potential risk. Methadone can pass into breast milk; therefore, breastfeeding decisions should be made in consultation with a healthcare professional.

To order Methasan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Methasan (methadone) is a long‑acting synthetic opioid, offering once‑daily dosing and a well‑established efficacy profile for opioid dependence. Compared with buprenorphine, methadone has a higher risk of respiratory depression but may provide more robust suppression of cravings for certain patients. Choice of therapy depends on individual patient factors and clinical judgment.

Methasan should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and do not store in bathrooms or other humid environments.

Methasan is administered orally, typically as a tablet or solution taken by mouth. The exact form and dosing schedule are determined by the prescribing clinician, who will provide instructions on how and when to take the medication for optimal effect.

The most serious risks include respiratory depression, which can be life‑threatening, and cardiac arrhythmias such as QT‑interval prolongation that may lead to torsades de pointes. Patients should be monitored closely for signs of these conditions, especially during dose initiation or when interacting drugs are present.

Methasan should be avoided in individuals with known hypersensitivity to methadone, those with significant uncontrolled cardiac arrhythmias, severe respiratory insufficiency, or in patients taking other potent CNS depressants without close medical supervision. Contraindications are determined by the prescribing healthcare professional.